SYD 003

Drug Profile

SYD 003

Alternative Names: SYD003

Latest Information Update: 26 Jul 2016

Price : $50

At a glance

  • Originator Synovo
  • Class
  • Mechanism of Action Immunomodulators; P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Pancreatic cancer

Most Recent Events

  • 26 Jul 2016 Preclinical trials in Pancreatic cancer in Germany (PO)
  • 20 Oct 2014 SYD 003 receives Orphan Drug status for Pancreatic cancer in USA
  • 22 Aug 2014 SYD 003 receives Orphan Drug status for Pancreatic cancer in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top